Efficacy and patients Satisfaction of sub lingual and oral captopril in hypertensive patient

Comparison of efficacy and patients satisfaction of sub lingual and oral captopril patients with hypertension

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015110924963N1

Enrollment

100

Registered

2015-12-24

Start date

2015-12-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Sub Lingual Captopril 25 mg, single dose. Intervention 2: Oral Captopril, 25 mg, single dose.

Treatment - Drugs

Sub Lingual Captopril 25 mg, single dose

Oral Captopril, 25 mg, single dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion: blood pressure 160/100 and more than exclusion: evidence of existence of acute ischemic heart disease; chest pain; dynamic change in EKG; heart failure; pulmonary edema; dissection of aorta; encephalopathy due to hypertension; seizure; loss of consciousness; cerebrovascular accident(ischemic , hemorrhagic); acute and chronic renal failure; history of pheochromocytoma; previous history of bilateral renal artery stenosis; pregnancy; hypertension after surgery; diastolic blood pressure >120; history of allergic reaction to captopril.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Systolic Blood Pressure. Timepoint: 10,20,30,45,60,90,120 min after drug administration. Method of measurement: blood pressure cuff, mmhg.;Diastolic Blood Pressure. Timepoint: 10,20,30,45,60,90,120 min after drug administration. Method of measurement: blood pressure cuff, mmhg.;Pulse rate. Timepoint: 10,20,30,45,60,90,120 min after drug administration. Method of measurement: Per Min.;Respiratory Rate. Timepoint: 10,20,30,45,60,90,120 min after drug administration. Method of measurement: Per Min.	—

Measure

Time frame

Systolic Blood Pressure. Timepoint: 10,20,30,45,60,90,120 min after drug administration. Method of measurement: blood pressure cuff, mmhg.;Diastolic Blood Pressure. Timepoint: 10,20,30,45,60,90,120 min after drug administration. Method of measurement: blood pressure cuff, mmhg.;Pulse rate. Timepoint: 10,20,30,45,60,90,120 min after drug administration. Method of measurement: Per Min.;Respiratory Rate. Timepoint: 10,20,30,45,60,90,120 min after drug administration. Method of measurement: Per Min.

—

Secondary

Measure	Time frame
Vomiting. Timepoint: after 2 hours. Method of measurement: Questionnare.;Headache. Timepoint: after 2 hours. Method of measurement: Questionnare.;Nausea. Timepoint: after 2 hours. Method of measurement: Questionnare.;Muscular Cramp. Timepoint: after 2 hours. Method of measurement: Questionnare.;Cough. Timepoint: after 2 hours. Method of measurement: Questionnare.;Cutaneous Rash. Timepoint: after 2 hours. Method of measurement: Questionnare.	—

Measure

Time frame

Vomiting. Timepoint: after 2 hours. Method of measurement: Questionnare.;Headache. Timepoint: after 2 hours. Method of measurement: Questionnare.;Nausea. Timepoint: after 2 hours. Method of measurement: Questionnare.;Muscular Cramp. Timepoint: after 2 hours. Method of measurement: Questionnare.;Cough. Timepoint: after 2 hours. Method of measurement: Questionnare.;Cutaneous Rash. Timepoint: after 2 hours. Method of measurement: Questionnare.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMania Armin

Shahrood Islamic Azad Universty

mania_armin@yahoo.com+98 23 3239 0077

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026